Moerae Matrix: <b>Moerae Matrix</b> Initiates Phase 1 Clinical Trial Of MMI-0100, A First-In-Class Inhibitor Of MK2, For Treatment Of Idiopathic Pulmonary Fibrosis

/www.biospace.com/enewsletter.aspx?typeseo-article&sourcenews-signup" ALT"free biotech news">/enewsletters.biospace.com/images/news/cta-latest-biotech-news.jpg" ALIGN"bottom" USEMAP"#cta-BiotechNews" border"0" alt"Get the latest biotech news where you want it. Sign up for the...